Advanced and Metastatic Colorectal Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Approximately
25% of patients are diagnosed with metastatic colorectal cancer, and roughly
50%-60% of those initially diagnosed with colorectal cancer progress to develop
metastatic disease. Visceral obesity has been linked to adverse effects on CRC
prognosis in men, with about a quarter attributable to genetic predisposition.
The liver is the most common site for colorectal cancer metastases, extending
to the lungs, bones, brain, or spinal cord. The development period for CRC
typically spans several years, underscoring the importance of early diagnosis.
Factors such as a previous cancer diagnosis, history of colon polyps,
inflammatory bowel diseases, diabetes mellitus, or cholecystectomy can increase
the risk of CRC. Surgery is the primary treatment for colon cancer, while
chemotherapy is often used as an adjuvant therapy. Approximately 40% of CRC
cases with RAS wild type are responsive to anti-epidermal growth factor
receptor (anti-EGFR) monoclonal antibody (mAB) therapy. Metastatic colorectal
cancer (mCRC) maintains a dismal prognosis, with an estimated 14% 5-year
survival rate. Unlike early-stage CRC, which can be treated effectively with
surgery and adjuvant chemotherapy, mCRC remains challenging due to
therapy-resistant metastasis-competent cells. Common signs of colorectal cancer
include frequent bowel movements, narrow stools, dark stools with blood,
fatigue, reduced appetite, unexplained weight loss, and gas pains or stomach
cramps.
·
The American Cancer Society (ACS) reports an
average five-year relative survival rate of 72% for regional metastatic colon
cancer and 13% for distant cases. According to the ACS, the five-year survival
rate estimate for metastatic rectal cancer is 74% for regional cancer and 17%
for distant cancer.
Thelansis’s
“Advanced and Metastatic Colorectal Cancer Market Outlook, Epidemiology,
Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers
disease overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Advanced
and Metastatic Colorectal Cancer treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Advanced and
Metastatic Colorectal Cancer across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Advanced
and Metastatic Colorectal Cancer Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Advanced
and Metastatic Colorectal Cancer, Advanced and Metastatic Colorectal Cancer market outlook, Advanced and Metastatic Colorectal
Cancer competitive landscape, Advanced and
Metastatic Colorectal Cancer market forecast,
Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)
Comments
Post a Comment